ABPI welcomes rare diseases research landscape report

The National Institute for Health and Care Research (NIHR) has today published the first Rare Diseases Research Landscape report, in collaboration with the Medical Research Council (MRC), industry, charities and the devolved administrations. It gives an overview of rare disease research being sponsored by Government, charities and industry in the UK. The ABPI contributed data from an industry perspective. 

Research is a global endeavour and industry has more than 700 medicines in development internationally for rare diseases. We want to make sure that UK patients can benefit from these advances. This report demonstrates the vibrant ecosystem for rare disease research that we have in the UK and underlines the importance of attracting industry to carry out clinical trials here. Janet Valentine, ABPI Director of Innovation and Research Policy

Welcoming the publication, Janet Valentine, the ABPI’s Director of Innovation and Research Policy said:

“This report is the first of its kind that maps out the UK rare diseases research landscape across Government, charity and industry. It provides a helpful overview of the research activities underway in conditions that affect 1 in 17 people in the UK.

“Research is a global endeavour and industry has more than 700 medicines in development internationally for rare diseases. We want to make sure that UK patients can benefit from these advances. This report demonstrates the vibrant ecosystem for rare disease research that we have in the UK and underlines the importance of attracting industry to carry out clinical trials here.”



TAGS
  • Rare diseases

Last modified: 22 September 2023

Last reviewed: 22 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.